EM Breakout -- Add Exposure
The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief...
928 Views
1k Views
Japan Pharma - Top Picks
While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP) is a contrarian call in anticipation of value...
771 Views
Japan CAR-T Therapy Landscape
Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...
1.3k Views
Takeda Pharmaceutical: Looking Forward To Pending Approvals and Late Stage Pipeline in FY27
Takeda Pharmaceutical reported lower FY26 revenue due to generic erosion, but expects growth in FY27 driven by new launches and core brands, with...
146 Views